INTERCEPT PHARMACEUTICALS, INC. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2014 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Intercept Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2014 to Q4 2022.
  • Intercept Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2022 was $418M, a 11% decline year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $418M -$51.5M -11% Dec 31, 2022 10-K 2023-03-02
Q4 2021 $469M +$33M +7.56% Dec 31, 2021 10-K 2023-03-02
Q4 2020 $436M +$82.8M +23.4% Dec 31, 2020 10-K 2022-03-02
Q4 2019 $354M +$14.8M +4.38% Dec 31, 2019 10-K 2021-02-25
Q4 2018 $339M +$56.1M +19.9% Dec 31, 2018 10-K 2020-02-25
Q4 2017 $283M +$59.3M +26.6% Dec 31, 2017 10-K 2019-03-01
Q4 2016 $223M +$76.2M +51.7% Dec 31, 2016 10-K 2018-02-28
Q4 2015 $147M +$42.5M +40.6% Dec 31, 2015 10-K 2017-03-01
Q4 2014 $105M Dec 31, 2014 10-K 2016-02-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.